Oneness Biotech Co., Ltd.
Taipei ExchangeTotal Valuation
Oneness Biotech Co., Ltd. carries a market capitalization of 24.02B, placing it among publicly traded companies globally. Its enterprise value stands at 21.33B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 24.02B |
| Enterprise Value | 21.33B |
Share Statistics
Oneness Biotech Co., Ltd. currently has 479.21M shares outstanding.
| Shares Outstanding | 479.21M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 206.30, and the price-to-book ratio stands at 7.08.
| PE Ratio | N/A |
| PS Ratio | 206.30 |
| PB Ratio | 7.08 |
| P/TBV Ratio | 2.81 |
| P/FCF Ratio | -61.41 |
| P/OCF Ratio | -57.88 |
Enterprise Valuation
| EV / Sales | 165.20 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 13.97 |
Financial Position
Oneness Biotech Co., Ltd. maintains a current ratio of 11.81, meaning it holds 11.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 3.54, indicating elevated leverage, while an interest coverage ratio of -89.77 demonstrates limited ability to service its debt obligations.
| Current Ratio | 11.81 |
| Quick Ratio | 11.17 |
| Debt / Equity | 3.54 |
| Debt / EBITDA | -0.46 |
| Interest Coverage | -89.77 |
Financial Efficiency
| Return on Equity (ROE) | -28.23 |
| Return on Assets (ROA) | -8.23 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 21.22 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.78 |
Taxes
Over the trailing twelve months, Oneness Biotech Co., Ltd. has paid 3.47M in income taxes, reflecting an effective tax rate of 36.79.
| Income Tax | 3.47M |
| Effective Tax Rate | 36.79 |
Stock Price Statistics
Oneness Biotech Co., Ltd.'s stock has declined approximately -11.4841% over the past 52 weeks. The 50-day moving average sits at 52.34, while the 200-day moving average is 61.03.
| Beta (5Y) | N/A |
| 52-Week Price Change | -11.4841% |
| 50-Day Moving Average | 52.34 |
| 200-Day Moving Average | 61.03 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Oneness Biotech Co., Ltd. generated 129.12M in revenue and converted that into -1.04B in net income, yielding earnings per share of -2.21. EBITDA reached -799.08M, while operating income came in at -799.08M.
| Revenue | 129.12M |
| Gross Profit | 39.88M |
| Operating Income | -799.08M |
| Pretax Income | -1.06B |
| Net Income | -1.04B |
| EBITDA | -799.08M |
| EBIT | -799.08M |
| Earnings Per Share (EPS) | -2.21 |
Balance Sheet
Oneness Biotech Co., Ltd. holds 5.82B in cash and equivalents against 370.73M in total debt, resulting in a net debt position of -1.66B. Total book value stands at 3.76B, with working capital of 5.64B providing operational flexibility.
| Cash & Cash Equivalents | 5.82B |
| Total Debt | 370.73M |
| Net Debt | -1.66B |
| Equity (Book Value) | 3.76B |
| Book Value Per Share | 7.86 |
| Working Capital | 5.64B |
Cash Flow
Oneness Biotech Co., Ltd. produced -460.24M in operating cash flow over the past twelve months. After subtracting -26.50M in capital expenditures, free cash flow totaled -486.74M - equivalent to -1.02 per share.
| Operating Cash Flow | -460.24M |
| Capital Expenditures | -26.50M |
| Free Cash Flow | -486.74M |
| FCF Per Share | -1.02 |
Margins
Oneness Biotech Co., Ltd. operates with a gross margin of 30.88, reflecting its pricing power and cost economics. The operating margin of -618.85 and net profit margin of -809.13 provide insight into operational efficiency.
| Gross Margin | 30.88 |
| Operating Margin | -618.85 |
| Pretax Margin | -817.87 |
| Profit Margin | -809.13 |
| EBITDA Margin | -618.85 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 0.05 |
| FCF Yield | -1.63 |
Stock Splits
Oneness Biotech Co., Ltd.'s most recent stock split took place on July 26, 2024 with a 1000:1049 split ratio.
| Last Split Date | 7/26/2024 |
| Split Ratio | 1000:1049 |
Scores
Oneness Biotech Co., Ltd. posts an Altman Z-Score of 12.98, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 12.98 |